Because metabolic abnormalities caused by metabolic syndrome have a great impact on liver carcinogenesis, we considered the possibility that metabolic disorders, such as insulin resistance and activation of the IGF/IGF-1R axis, might be effective targets in the prevention of HCC, and we tested this using animal models of obesity- and diabetes-related liver carcinogenesis. The gene discussed is IGF1; the disease is metabolic syndrome.